3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Melanoma
16
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Brain Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Gallbladder Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Xanthogranuloma, Juvenile
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Clear Cell
1
Neoplasms, Unknown Primary
1
Microsatellite Unstable Colorectal Cancer
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Inflammatory Breast Neoplasms
1
Histiocytosis, Sinus
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Histiocytic Disorders, Malignant
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
41
fludarabine
35
Tacrolimus
28
Mycophenolic Acid
27
Whole-Body Irradiation
25
Busulfan
24
fludarabine phosphate
21
Melphalan
19
thymoglobulin
16
Antilymphocyte Serum
16
Methotrexate
13
Thiotepa
12
Stem Cell Transplantation
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Filgrastim
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Nivolumab
5
ruxolitinib
4
merphos
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
Cord Blood Stem Cell Transplantation
4
Bendamustine Hydrochloride
4
tocilizumab
3
itacitinib
3
fedratinib
3
dabrafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Neoplasms
×
cobimetinib
×
Clear all
NCT05159245
2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2
Recruiting
250 enrolled